Michael Gelband’s PTC Therapeutics PTCT Stock Holding History

Michael Gelband’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.67M	Buy	+57,278	New	+$4.14M	0.03%	522
2026 Q1	–	Sell	-11,057	Closed	-$840K	–	1993
2025 Q4	$840K	Sell	11,057 -62,401	-85%	-$4.53M	0.01%	1054
2025 Q3	$4.51M	Buy	+73,458	New	+$3.83M	0.05%	450
2024 Q3	–	Sell	-68,020	Closed	-$2.08M	–	2004
2024 Q2	$2.08M	Buy	+68,020	New	+$2.2M	0.01%	762
2023 Q4	–	Sell	-23,483	Closed	-$526K	–	1940
2023 Q3	$526K	Sell	23,483 -41,599	-64%	-$1.55M	0.01%	1226
2023 Q2	$2.65M	Buy	+65,082	New	+$3.18M	0.02%	698
2023 Q1	–	Sell	-7,466	Closed	-$285K	–	2058
2022 Q4	$285K	Sell	7,466 -34,254	-82%	-$1.42M	﹤0.01%	1369
2022 Q3	$2.09M	Buy	41,720 +29,290	+236%	+$1.44M	0.03%	785
2022 Q2	$498K	Buy	+12,430	New	+$436K	0.01%	1352
2021 Q3	–	Sell	-9,524	Closed	-$403K	–	2524
2021 Q2	$403K	Buy	9,524 +1,446	+18%	+$62K	﹤0.01%	1562
2021 Q1	$382K	Buy	+8,078	New	+$480K	0.01%	1522
2019 Q4	–	Sell	-6,000	Closed	-$203K	–	1816
2019 Q3	$203K	Buy	+6,000	New	+$261K	0.01%	1119

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Michael Gelband's PTCT Position: Q2 2026 in Review

Michael Gelband opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 57,278 shares worth $4.67M. The stake represents 0.03% of the portfolio and ranks #522 among its holdings. This is a return to the name: Michael Gelband previously reported a position in PTCT as recently as Q4 2025.

Michael Gelband first reported a position in PTCT in Q3 2019 and has held it in 12 quarters since. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Michael Gelband held 57,278 shares of PTC Therapeutics worth $4.67M as of Q2 2026.
PTC Therapeutics was a new Michael Gelband position in Q2 2026.
PTC Therapeutics made up 0.03% of Michael Gelband's portfolio in Q2 2026, its #522 holding.
Michael Gelband first reported a position in PTC Therapeutics in Q3 2019 and has held it in 12 quarters since.
380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.